Brown Brothers Harriman & Co. Has $50,000 Stock Holdings in Genelux Co. (NASDAQ:GNLX)

Brown Brothers Harriman & Co. grew its stake in Genelux Co. (NASDAQ:GNLX) by 76.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,075 shares of the company’s stock after purchasing an additional 9,114 shares during the quarter. Brown Brothers Harriman & Co. owned approximately 0.06% of Genelux worth $50,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of GNLX. Point72 Asia Singapore Pte. Ltd. acquired a new position in Genelux in the 2nd quarter valued at about $39,000. Cubist Systematic Strategies LLC bought a new stake in Genelux in the 2nd quarter valued at about $56,000. Miracle Mile Advisors LLC acquired a new position in shares of Genelux during the 2nd quarter worth approximately $58,000. LifeSteps Financial Inc. grew its position in shares of Genelux by 50.2% during the 2nd quarter. LifeSteps Financial Inc. now owns 66,536 shares of the company’s stock worth $130,000 after purchasing an additional 22,227 shares in the last quarter. Finally, AMG National Trust Bank increased its holdings in shares of Genelux by 49.7% during the second quarter. AMG National Trust Bank now owns 75,351 shares of the company’s stock worth $147,000 after purchasing an additional 25,000 shares during the period. Institutional investors and hedge funds own 37.33% of the company’s stock.

Wall Street Analyst Weigh In

GNLX has been the subject of several recent research reports. Guggenheim assumed coverage on Genelux in a research report on Tuesday, October 29th. They set a “buy” rating and a $8.00 price target on the stock. HC Wainwright reduced their target price on Genelux from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Roth Mkm assumed coverage on Genelux in a research note on Tuesday, August 27th. They issued a “buy” rating and a $10.00 price target for the company. Finally, Roth Capital upgraded shares of Genelux to a “strong-buy” rating in a research note on Tuesday, August 27th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $18.25.

Insider Activity at Genelux

In other news, major shareholder Aladar Szalay sold 42,818 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.09, for a total value of $89,489.62. Following the completion of the transaction, the insider now owns 739,821 shares of the company’s stock, valued at approximately $1,546,225.89. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 132,387 shares of company stock valued at $324,342 over the last ninety days. 9.30% of the stock is owned by corporate insiders.

Genelux Stock Performance

Shares of GNLX stock opened at $2.69 on Friday. Genelux Co. has a fifty-two week low of $1.60 and a fifty-two week high of $16.60. The stock’s fifty day moving average price is $2.65 and its two-hundred day moving average price is $2.52. The company has a market cap of $92.91 million, a PE ratio of -2.83 and a beta of -1.85.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.